Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical, Inc. (RARE)
:RARE
RESEARCH TOOLSreports
Holding RARE?
Track your performance easily
RARE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.02 - $60.37
Previous CloseN/A
Volume75.38K
Average Volume (3M)944.99K
Market Cap
$3.70B
Enterprise Value$5.60B
Total Cash (Recent Filing)$380.15M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Feb 13, 2025EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding92,344,270
10 Day Avg. Volume1,255,508
30 Day Avg. Volume944,988
Standard Deviation0.14
R-Squared0.05
Alpha0.00275
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.24
Price to Cash Flow (P/CF)-14.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue10.71
Enterprise Value/Gross Profit14.39
Enterprise Value/Ebitda-14.42
Forecast
1Y Price Target
$88.87Price Target Upside116.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Ultragenyx Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe pivotal ORBIT study of setrusumab in osteogenesis imperfecta is proceeding to the second interim analysis, highlighting ongoing clinical advancement.
Financial PerformanceUltragenyx reported preliminary 2024 total revenues of $555-560M, exceeding the consensus of $536M.
Regulatory ProgressUltragenyx submitted the Biologics License Application for UX111, demonstrating forward progress in their gene therapy development.
Bears Say
Financial ManagementNet cash used in operations is expected to be significant, highlighting burn and runway management as a critical focus for investors.
Regulatory ChallengesPotential clinical trial failures and regulatory approval challenges present significant risks to the investment.
Sales PerformancePeak sales estimates are modestly lowered for Dojolvi and Evkeeza, indicating potential weakness in market performance.
---
Ownership Overview
3.93% Insiders
29.88% Mutual Funds
0.20% Other Institutional Investors
52.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical, Inc.’s price range in the past 12 months?
Ultragenyx Pharmaceutical, Inc. lowest stock price was $37.02 and its highest was $60.37 in the past 12 months.
What is Ultragenyx Pharmaceutical, Inc.’s market cap?
Ultragenyx Pharmaceutical, Inc.’s market cap is $3.70B.
When is Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date?
Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date is Feb 13, 2025 which is in 27 days.
How were Ultragenyx Pharmaceutical, Inc.’s earnings last quarter?
Ultragenyx Pharmaceutical, Inc. released its earnings results on Nov 05, 2024. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.484 by $0.084.
Is Ultragenyx Pharmaceutical, Inc. overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical, Inc.’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical, Inc. pay dividends?
Ultragenyx Pharmaceutical, Inc. does not currently pay dividends.
What is Ultragenyx Pharmaceutical, Inc.’s EPS estimate?
Ultragenyx Pharmaceutical, Inc.’s EPS estimate is -1.34.
How many shares outstanding does Ultragenyx Pharmaceutical, Inc. have?
Ultragenyx Pharmaceutical, Inc. has 92,344,270 shares outstanding.
What happened to Ultragenyx Pharmaceutical, Inc.’s price movement after its last earnings report?
Ultragenyx Pharmaceutical, Inc. reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.484. Following the earnings report the stock price went down -3.181%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical, Inc.?
Among the largest hedge funds holding Ultragenyx Pharmaceutical, Inc.’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical, Inc.’s shares valued at 284M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.87 (116.86% Upside)
$88.87 (116.86% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 99.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $908.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.32%
12-Months-Change
Fundamentals
Return on Equity
-295.34%
Trailing 12-Months
Asset Growth
24.25%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
RARE Company Deck
---
RARE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth and significant advancements in clinical programs, particularly in gene therapy and commercialization efforts. However, high operating expenses and ongoing cash burn remain challenges.Read More>---
RARE Stock 12 Month Forecast
Average Price Target
$88.87
▲(116.86% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Alnylam Pharma
―
Sarepta Therapeutics
―
Regeneron
―
Crispr Therapeutics AG
―
Best Analysts Covering RARE
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
-1.17%
reiterated a buy rating 7 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of -1.17% per trade.
---